- Home
- TNXP vs VALU Comparison
TNXP vs VALU Comparison
Compare TNXP & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- VALU
- Stock Information
- Founded
- TNXP 2007
- VALU 1931
- Country
- TNXP United States
- VALU United States
- Employees
- TNXP N/A
- VALU N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- VALU Investment Managers
- Sector
- TNXP Health Care
- VALU Finance
- Exchange
- TNXP Nasdaq
- VALU Nasdaq
- Market Cap
- TNXP 335.6M
- VALU 345.7M
- IPO Year
- TNXP N/A
- VALU N/A
- Fundamental
- Price
- TNXP $28.35
- VALU $38.60
- Analyst Decision
- TNXP Buy
- VALU
- Analyst Count
- TNXP 1
- VALU 0
- Target Price
- TNXP $70.00
- VALU N/A
- AVG Volume (30 Days)
- TNXP 1.2M
- VALU 6.6K
- Earning Date
- TNXP 11-11-2025
- VALU 09-15-2025
- Dividend Yield
- TNXP N/A
- VALU 3.40%
- EPS Growth
- TNXP N/A
- VALU 6.17
- EPS
- TNXP N/A
- VALU 2.26
- Revenue
- TNXP $9,831,000.00
- VALU $34,801,000.00
- Revenue This Year
- TNXP $14.79
- VALU N/A
- Revenue Next Year
- TNXP $933.49
- VALU N/A
- P/E Ratio
- TNXP N/A
- VALU $16.95
- Revenue Growth
- TNXP N/A
- VALU N/A
- 52 Week Low
- TNXP $6.76
- VALU $32.94
- 52 Week High
- TNXP $130.00
- VALU $57.68
- Technical
- Relative Strength Index (RSI)
- TNXP 41.38
- VALU 53.04
- Support Level
- TNXP $26.89
- VALU $38.24
- Resistance Level
- TNXP $29.19
- VALU $39.35
- Average True Range (ATR)
- TNXP 2.18
- VALU 0.74
- MACD
- TNXP 0.39
- VALU 0.10
- Stochastic Oscillator
- TNXP 56.46
- VALU 73.50
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About VALU Value Line Inc.
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.